33 results about "DLK1" patented technology

The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or avariant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAsare over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention ofan Atrogin-1 - dependent muscular disease and cachexia.

The invention relates to application of DLK1 in diagnosis and prognosis of a liver cancer. Specifically speaking, the invention provides application of preadipocyte factor-1 (DLK1 protein) in (a) preparation of a diagnostic reagent or kit for prognosis detection of a liver cancer and (b) preparation of a diagnostic reagent or kit for serum detection of a liver cancer. The invention also provides corresponding detection kits.

The invention discloses sgRNA for up-regulating non-coding RNA expression in a human DLK1-DIO3 imprinted domain, a recombinant plasmid and a cell line. The sgRNA sequence is shown as SEQ ID NO. 1, andspecifically as 5'-TTTATATGGAGGCGCAGAAG-3'; the method comprises the steps of: synthesizing a nucleic acid fragment of a sgRNA sequence and inserting into a multiple cloning site of the MS2-P65-HSF1expression plasmid vector and transforming, and selecting a monoclonal strain, extracting the recombinant plasmid of MS2-P65-HSF1-sgRNA-DLK1-DIO3, and transfecting the recombinant plasmid to the target cell line which is pre-transfected with dCAS9-VP64 plasmid to obtain the cell strain for up-regulating non-coding RNA expression in the DLK1-DIO3 imprinted domain. The application can rapidly, easily and accurately up-regulate the expression of non-coding RNA on the DLK1-DIO3 imprinted domain of the cell strain.

The invention relates to key genes, microRNAs and other non-coding RNAs, or a combination thereof used for identifying or regulating cell pluripotency. The invention is characterized in that the key genes, microRNAs, other non-coding RNAs or a combination is highly expressed in the stem cell with complete pluripotency and the expression is obviously repressed or silent in the stem cell without complete pluripotency. The genes, microRNAs and other non-coding RNAs are the genes, microRNAs and other non-coding RNAs positioned in the chromosome imprinting region named as Dlk1-Dio3 on the long arm of mouse chromosome 12 and the genes, microRNAs and other non-coding RNAs in the genome collinearity regions of other mammals, which have 70%-100% of homology. The invention also relates to applications of the genes, microRNAs and other non-coding RNAs, or the combination thereof used for identifying the pluripotency of the stem cell and regulating cell pluripotency, applications in stem cell typing, applications for regulating the cell pluripotency and the pluripotency state and level of the cell, applications in disease treatment, and applications in the drug target development of tumor treatment or the development of antitumor drugs.

Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used separately. Genes found to be epigenetically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ARTS-1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.

The invention relates to application of a DLK1 (delta drosophila homolog-like1) gene in preparation of a gastrointestinal stromal tumor diagnostic reagent. The new discovery of the invention can be applied to development of drugs or kits based on RT-PCR, PCR, immunodetection, in-situ hybridization, gene chip and other technologies for diagnosis of gastrointestinal stromal tumors. The invention puts forward for the first time that detection based on DLK1 gene and its products in serum / tissue can be utilized to achieve early diagnosis of GIST or carry out prognosis on GIST patients undergoing surgical treatment, the high-throughput chip screening + real-time quantitative PCR validation established on the gene level and large sample clinical sample validation on the protein level have reliable result, and DLK1 can significantly distinguish tumors and nontumors, high-risk tumors and low-risk tumors both on the gene level and protein level, and the result repeatability is good. Thus, DLK1 gene has good clinical application value.

The invention discloses an ELISA kit for detecting human serum DLK1 protein and its application. The antigen of the ELISA kit of the present invention adopts recombinant human DLK1 antigen. The detection method of the present invention has high sensitivity and specificity, and can quickly detect the expression of DLK1 and liver cancer and hepatoblastoma. The ELISA kit of the present invention has broad application in the prevention and diagnosis of liver cancer and hepatoblastoma Application prospects.